Follicle-stimulating hormone insensitivity

From WikiMD's Medical Encyclopedia

Revision as of 04:51, 4 April 2025 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


Follicle-stimulating hormone insensitivity
Synonyms FSH insensitivity, FSH resistance
Pronounce N/A
Specialty N/A
Symptoms Infertility, amenorrhea, oligospermia, delayed puberty
Complications Infertility
Onset Puberty
Duration Lifelong
Types N/A
Causes Mutations in the FSHR gene
Risks Genetic predisposition
Diagnosis Genetic testing, hormone level testing
Differential diagnosis Hypogonadotropic hypogonadism, Kallmann syndrome
Prevention N/A
Treatment Assisted reproductive technology, hormone replacement therapy
Medication Gonadotropins, estrogen, testosterone
Prognosis N/A
Frequency Rare
Deaths N/A


Follicle-stimulating hormone insensitivity (FSH insensitivity), also known as ovarian insensitivity to FSH in females, is a rare autosomal recessive genetic and endocrine syndrome affecting both females and males, though females typically experience more severe symptoms. This condition is characterized by a resistance or complete insensitivity to the effects of follicle-stimulating hormone (FSH), a gonadotropin responsible for stimulating estrogen production by the ovaries in females and maintaining fertility in both sexes.

Presentation

In females, FSH insensitivity manifests as hypergonadotropic hypogonadism, characterized by decreased or lack of production of sex steroids by the gonads despite high circulating levels of gonadotropins. This leads to reduced or absent puberty, amenorrhea (lack of menstruation), and infertility. Males with FSH insensitivity typically experience varying degrees of infertility and may present with decreased sperm production.

Related Condition

A related condition, luteinizing hormone (LH) insensitivity, presents with similar symptoms but with reversals in symptomatology between sexes. Males with LH insensitivity may present with hypogonadism and sexual infantilism, while females may experience problems with fertility. Males with LH insensitivity may also present with feminized or ambiguous genitalia, a feature not observed in females with FSH insensitivity.

Signs

In females with FSH insensitivity, ovarian follicles and granulosa cells exhibit diminished development, resulting in low to normal estrogen levels, elevated gonadotropin levels, and reduced inhibin B levels. Males may show diminished Sertoli cell proliferation, moderately elevated FSH levels, normal to slightly elevated LH levels, normal testosterone levels, and reduced inhibin B levels.

Symptoms

In females, FSH insensitivity presents as hypergonadotropic hypogonadism, leading to delayed, reduced, or absent puberty, sexual infantilism, reduced uterine volume, and osteoporosis. Ovarian dysgenesis or failure may result in amenorrhea, infertility, and normal to slightly enlarged ovaries. Males may experience partial or complete infertility, reduced testicular volume, and oligozoospermia (reduced spermatogenesis).

Cause

FSH insensitivity is caused by inactivating mutations of the follicle-stimulating hormone receptor (FSHR), resulting in insensitivity of the receptor to FSH. This leads to an inability of granulosa cells in ovarian follicles to respond to FSH in females, resulting in diminished estrogen production and menstrual irregularities, and an inability of Sertoli cells in the testicles to respond to FSH in males, leading to impaired spermatogenesis.

Diagnosis

The diagnosis of FSH insensitivity involves clinical evaluation and genetic testing to identify mutations in the FSHR gene. However, this section requires expansion.

Treatment

Hormone replacement therapy with estrogen may be used to alleviate symptoms of hypoestrogenism in females. Currently, there are no known treatments for infertility caused by FSH insensitivity in either sex. Further research is needed to explore potential therapeutic options. This template is no longer used; please see Template:Endocrine pathology for a suitable replacement





This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.